Why the study?
Does adriamycin induce objective remissions and what is its toxicity profile in patients with disseminated neoplasia?
Does adriamycin induce objective remissions and what is its toxicity profile in patients with disseminated neoplasia?
Adriamycin is an active chemotherapeutic agent that produces prompt remissions, but it is associated with cumulative cardiotoxicity including irreversible congestive heart failure.
Answers are grounded in this paper and cite their sources.
Supports adriamycin evaluation in lymphomas, sarcomas, and breast cancer; leaves open safe dosing strategies given cardiotoxicity risk.
Four hundred and seventy-two patients with disseminated neoplasia were treated with two or more doses of adriamycin. The initial dose for “good risk” patients was 75 mg/m2 every 3 weeks, and for “poor risk” patients was 60 mg/m2 every 3 weeks. Objective remissions were seen in 118/472 patients, with best results noted in lymphomas (21/48), sarcomas (21/64), and carcinoma of the breast (16/50). Eighty-nine per cent of remissions occurred within three courses. Hematopoietic toxic effects were seen in 73% of patients; nausea, vomiting, and/or stomatitis were observed in 43%. Changes in electrocardiograms were seen in 42/472 patients after cumulative doses of adriamycin ranging from 45 mg/m2 to 600+mg/m2. Irreversible congestive heart failure occurred in two patients after cumulative doses of 555 mg/m2 and 825 mg/m2, respectively. It is concluded that adriamycin is an active agent, most remissions occur promptly, and significant cardiotoxic reactions appear to be cumulative.
No takes yet. Share an insight, caveat, or question.
OʼBryan et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: